![Les fonds conseillés par Motion Equity Partners annoncent la signature de l'acquisition du Laboratoire Equilibre Attitude - Motion Equity Partners Les fonds conseillés par Motion Equity Partners annoncent la signature de l'acquisition du Laboratoire Equilibre Attitude - Motion Equity Partners](https://www.motionequitypartners.com/wp-content/uploads/2018/12/EA-Pharma-brands-vf.png)
Les fonds conseillés par Motion Equity Partners annoncent la signature de l'acquisition du Laboratoire Equilibre Attitude - Motion Equity Partners
![Equilibre Attitude (EA Pharma) strengthens its expertise in Oligotherapy with the acquisition of Labcatal, its third build-up under Motion ownership - Motion Equity Partners Equilibre Attitude (EA Pharma) strengthens its expertise in Oligotherapy with the acquisition of Labcatal, its third build-up under Motion ownership - Motion Equity Partners](https://www.motionequitypartners.com/wp-content/uploads/2020/02/New-Project-20-1-1-550x325.jpg)
Equilibre Attitude (EA Pharma) strengthens its expertise in Oligotherapy with the acquisition of Labcatal, its third build-up under Motion ownership - Motion Equity Partners
![EA Pharma strengthens its international presence with the acquisition of the Spanish Group DRASANVI, its fourth build-up with Motion - Motion Equity Partners EA Pharma strengthens its international presence with the acquisition of the Spanish Group DRASANVI, its fourth build-up with Motion - Motion Equity Partners](https://www.motionequitypartners.com/wp-content/uploads/2021/08/New-Project-1.jpg)
EA Pharma strengthens its international presence with the acquisition of the Spanish Group DRASANVI, its fourth build-up with Motion - Motion Equity Partners
![EA Pharma pursue its international expansion with the acquisition of the Italian brand Stardea - Motion Equity Partners EA Pharma pursue its international expansion with the acquisition of the Italian brand Stardea - Motion Equity Partners](https://www.motionequitypartners.com/wp-content/uploads/2022/07/New-Project-1-1.jpg)